About Xilis
Xilis is a Healthcare company based in Durham (United States) founded in 2019 by Hans Clevers. Micro-organ sphere technologies for oncology drug discovery are developed. Xilis has raised $116.26 million across 6 funding rounds from investors including ARE, Duke University and EQT. The company has 55 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is XILIS INC. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Xilis was founded in 2019 and is based in Durham, United States. A platform for drug discovery and precision therapy in oncology is provided by the company. Micro-organ sphere technologies are employed to support rapid diagnostics, personalized drug screening, and scalable patient-derived models. These capabilities are applied in immuno-oncology drug discovery, focusing on oncology sector operations.
- Total Equity Funding$116.26M (USD)
in 6 rounds
- InvestorsARE
& 13 more
- Employee Count55
Funding Insights of Xilis
Xilis has successfully raised a total of $116.26M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $116.26M
- Total Rounds 6
- First Round $3M
(Dec 2019)
- Investors Count 14
All 6 funding rounds of Xilis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | Debt – Conventional | – | – | – | |
| Apr 2025 | $19.41M | Series B | – | – | – |
| Jul 2022 | $19M | Series A | – | FPV Ventures | |
| Jul 2021 | $70M | Series A | – | Mubadala | |
| May 2020 | $4.85M | Series A | – | – | – |
| Dec 2019 | $3M | Seed | – | – | – |
14 investors in total: 14 institutional.
Investors in Xilis
Xilis has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Duke University and EQT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Seed & early stage VC firm investing the US | 2013 | pear.vc | San Francisco, United States | |
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
Early-stage investments in tech sectors are managed by the firm. | twosigmaventures.com | New York, United States | ||
Investments in technology startups are made by Felicis Ventures. | felicis.com | Menlo Park, United States | ||
Early stage life science startups are supported by investments. | alix.vc | |||
Investments are provided to mission-driven founders by FPV Ventures. | fpvventures.com | San Francisco, United States | ||
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
| dukeangelnetwork.duke.edu |
Investor details for Xilis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Xilis
1 people are tracked at Xilis (1 in leadership); the tracked headcount is 55.
| Name | Role | Group |
|---|---|---|
Hans Clevers | Co-Founder | Leadership |
Complete people profiles for Xilis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Xilis
3 dated milestones of Xilis across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Xilis is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Debt – Conventional,.
Competitors of Xilis
Xilis has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. |
Detailed competitors of Xilis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Xilis
The website of Xilis (xilis.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▼ 5% vs previous month
Websites whose visitors overlap most with Xilis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| altisbiosystems.com | 100% | 16.6K | #1,779,798 | View details | |
| catawbaresearch.com | 100% | 3.5K | #5,071,999 | View details | |
| saperebio.com | 93% | View details | |||
| lifeeditinc.com | 90% | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Xilis (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xilis
Complete news archive for Xilis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xilis
Xilis was founded in 2019.
Xilis is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Xilis is a funded company, having raised a total of $116.26M across 6 funding rounds to date. The company's 1st funding round was a Seed of $3M, raised on Dec 2019.
Xilis has 55 employees.
Xilis was founded in 2019 and is based in Durham, United States. A platform for drug discovery and precision therapy in oncology is provided by the company. Micro-organ sphere technologies are employed to support rapid diagnostics, personalized drug screening, and scalable patient-derived models. These capabilities are applied in immuno-oncology drug discovery, focusing on oncology sector operations.
Xilis's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.
Xilis has 14 investors. Key investors include ARE, Duke University, EQT, Mubadala, and Pear VC.
Xilis operates through Xilis Inc.